Skip to content

Guilford Genomic Medicine Initiative (GGMI)

Guilford Genomic Medicine Initiative (GGMI)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01372553
Acronym
GGMI
Enrollment
1184
Registered
2011-06-14
Start date
2009-10-31
Completion date
2012-04-30
Last updated
2014-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Colon Cancer, Ovarian Cancer, Thrombophilia

Keywords

Primary care, Family History, Risk Stratification, Cancer, Thrombosis

Brief summary

* Genomic medicine, using genetic information to improve health outcomes, is heralded as the answer to rising medical costs by focusing on prevention and tailored care. Despite its potential, little investigation has focused on how genomic medicine can be applied in health care. To be effective, it requires new ways to learn, deliver, and communicate medical information. It will also raise new ethical questions. * The overall goal of Guilford Genomic Medicine Initiative (GGMI) is to identify the specific challenges in re-structuring an existing medical system to integrate genomic medicine, and create solutions that can be used by other medical systems, such as the extensive military medical care system. To accomplish this goal, GGMI includes the development of a large-scale genomic medicine education initiative targeted at the community, providers, and patients, and a clinical systems model to implement strategies to facilitate the integration of genomic medicine into several pilot practices.

Interventions

None listed

Sponsors

Duke University
CollaboratorOTHER
University of North Carolina, Greensboro
CollaboratorOTHER
The Moses H. Cone Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* All patients scheduled for an upcoming well or new visit within the next 3 weeks with their primary care physician (at the two implementation clinics).

Exclusion criteria

* Non-english speaking * not consentable * adopted

Design outcomes

Primary

MeasureTime frameDescription
Evaluate effectiveness of family history collection and decision support for increasing appropriate referrals to genetic counselors for patients at risk of hereditary cancer syndromes1 yearchange in appropriate referal to genetic counseling one year before using MeTree compared to one year after.
Evaluate effectiveness of family history collection and decision support for increasing appropriate screening for breast, colon, and ovarian cancer1 yearCompare rate of appropriate screening for breast, colon, and ovarian cancer one year prior to using the family history decision support tool and one year after
Evaluate effectiveness of family history collection and decision support for appropriate risk-based management of thrombosisone yearEvaluate rate of appropriate genetic counseling and/or genetic testing one year prior to using the family history collection and decision support tool and one year after

Secondary

MeasureTime frameDescription
Measure physician experience with the MeTree system3 monthsEvaluate physicians' perceptions of satisfaction, the tool's impact on work load and its effectiveness via survey and informal interviews at 3 months.
Implementation parameters for MeTreeup to 2 yearsPart of the formative evaluation of the implementation process which includes other secondary measures as well as those related to impact on the clinic such as time to use the tool, questions asked while taking the tool, and resources and support that will be needed to implement the tool in a non-study environment
Measure patient-related outcomes associated with using the MeTree toolDay 1We assess satisfaction, comfort, anxiety, and preparedness associated with using the MeTree tool via survey immediately after completing the family history collection.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026